With a one year PEG ratio of 0.52, Erytech Pharma SA is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 6.33% of US stocks.
With a price/sales ratio of 29.11, Erytech Pharma SA has a higher such ratio than 93.21% of stocks in our set.
With a year-over-year growth in debt of 350.85%, Erytech Pharma SA's debt growth rate surpasses 95.21% of about US stocks.
Stocks that are quantitatively similar to ERYP, based on their financial statements, market capitalization, and price volatility, are ACIU, VCNX, NVEC, VNE, and CBIO.
ERYP's SEC filings can be seen here. And to visit Erytech Pharma SA's official web site, go to www.erytech.com.
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
ERYTECH Pharma (ERYP) inks at-the-market sales agreement with Cowen for the sale of ordinary shares in the form of American Depositary Shares (ADSs) for gross sales proceeds of up to $30M.The ATM program will be effective until September 21, 2023, unless terminated prior to such date. Net proceeds will be...